stockportfolio.pro
Supernus Pharmaceuticals, Inc. P/E Ratio 2010–2025
Supernus Pharmaceuticals, Inc. (SUPN) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -3.7%/yr over 15 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | — | — |
| FY 2024 | 27.39 | -98.1% |
| FY 2023 | 1447.00 | +4118.9% |
| FY 2022 | 34.30 | +15.3% |
| FY 2021 | 29.76 | +179.1% |
| FY 2020 | 10.66 | -5.6% |
| FY 2019 | 11.30 | -30.3% |
| FY 2018 | 16.20 | -56.1% |
| FY 2017 | 36.90 | +157.2% |
| FY 2016 | 14.35 | -70.1% |
| FY 2015 | 48.00 | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | — | — |
Source: Supernus Pharmaceuticals, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Supernus Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeSupernus Pharmaceuticals, Inc. — frequently asked questions
What is Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio?
Supernus Pharmaceuticals, Inc. (SUPN) reported price-to-earnings ratio of 27.39 for fiscal year 2024, per its SEC filings.
How has Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2010 and 2025, SUPN's price-to-earnings ratio declined at roughly 3.7% per year (compound annual rate), from 48.00 to 27.39.
Where does this data come from?
Figures are computed from Supernus Pharmaceuticals, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.